Acidity-Triggered Ligand-Presenting Nanoparticles To Overcome Sequential Drug Delivery Barriers to Tumors

Abstract

The success of cancer chemotherapy is impeded by poor drug delivery efficiency due to the existence of a series of pathophysiological barriers in the tumor. In this study, we reported a tumor acidity-triggered ligand-presenting (ATLP) nanoparticle for cancer therapy. The ATLP nanoparticles were composed of an acid-responsive diblock copolymer as a sheddable matrix and an iRGD-modified polymeric prodrug of doxorubicin (iPDOX) as an amphiphilic core. A PEG corona of the polymer matrix protected the iRGD ligand from serum degradation and nonspecific interactions with the normal tissues while circulating in the blood. The ATLP nanoparticles specifically accumulated at the tumor site through the enhanced permeability and retention (EPR) effect, followed by acid-triggered dissociation of the polymer matrix within the tumoral acidic microenvironment (pH ∼ 6.8) and subsequently exposing the iRGD ligand for facilitating tumor penetration and cellular uptake of the PDOX prodrug. Additionally, the acid-triggered dissociation of the polymer matrix induced a 4.5-fold increase of the fluorescent signal for monitoring nanoparticle activation in vivo. Upon near-infrared (NIR) laser irradiation, activation of Ce6-induced significant reactive oxygen species (ROS) generation, promoted drug diffusion inside the tumor mass and circumvented the acquired drug resistance by altering the gene expression profile of the tumor cells. The ATLP strategy might provide a novel insight for cancer nanomedicine.

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

“…A great number of nanoparticles have factored in the superiority of unique endogenous features in the tumor microenvironment, including specific proteases, hypoxia, and low extracellular pH, which allow nanosystems to accumulate in the pathologic sites and release the payloads in response to these stimuli for cancer diagnosis and treatment …”

Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines

“…Then, the elevated lysosomal cathepsin B in tumor cells further promoted gemcitabine (GEM) release for pancreatic tumor therapy (Figure B) . In another study, pH‐triggered cRGD targeting was integrated with PDT and MMP‐sensitive DOX release for improved tumor therapy …”

Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

“…developed tumor acidity‐triggered ligand‐presenting (ATLP) nanoparticles for breast cancer therapy which possesses functional components including protective PEG corona; amphiphilic core of pH‐responsive diblock copolymer matrix, poly(ethylene glycol)‐b‐poly(2‐(hexamethyleneimino) ethyl methacrylate) (PEG‐b‐PHMA, termed as PHMA), and iRGD‐decorated polymeric prodrug of doxorubicin (iPDOX). Upon EPR‐mediated accumulation of these NPs at the acidic tumor microenvironment, the matrix dissociated and exposed the tumor penetrating iRGD ligand for enhanced cellular internalization of PDOX . Zhu et al.…”